Chroma Therapeutics, GlaxoSmithKline deal

Chroma received an undisclosed milestone payment from GlaxoSmithKline under a 2009 deal under which the pharma's Centre of Excellence for External Drug Discovery received options to license exclusive, worldwide rights to four macrophage-targeted small molecule programs. The payment was triggered by GSK approving the advancement of CHR-5154 into clinical development. The histone deacetylase (HDAC) inhibitor is based on the biotech's esterase-sensitive motif (ESM) technology. Chroma received an undisclosed milestone payment in 2010 triggered by advancing CHR-5154 into preclinical development (see BioCentury, Aug. 30, 2010). ...